In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA rejects antibiotic non-inferiority studies for bronchitis

This article was originally published in Scrip

Executive Summary

A new US FDAdraft guideline formally rejects the use of non-inferiority studies in the development of antimicrobial drugs for acute bacterial exacerbations of chronic bronchitis (ABECB), making clear that only superiority trials are recommended. The document stresses the importance of clinical benefit as an outcome and relies heavily on the use of patient-reported measures in assessing efficacy.

You may also be interested in...



US FDA, Industry Share Early Lessons From Complex Innovative Trial Designs Program

Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.

US FDA Will Leverage Current Clinical Trial Data In Deciding On Post-COVID Flexibilities

Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.

Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19

Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel